(A) Overview of the key hypothesis, suggesting that TM5-ECL2 engagement by morphinan ligand with ring-C chair form leads to preferred G protein signaling, whereas TM2-TM3 engagement and ring-C boat …
(A-B) MP1104 (red) is a full agonist in hMOR in cAMP inhibition (N = 5) and Tango-arrestin recruitment assays (N = 5) compared to DAMGO (blue). (C–D) MP1104 (red) is a full agonist in hKOR in cAMP …
(A-B) MP1207 (orange) and MP1208 (green) are full agonists at hKOR in cAMP inhibition (N = 3) and partial agonists in Tango-arrestin recruitment assays (N = 3) compared to U50, 488 (purple). (C–D) …
(A) Docking of MP1202 (green sticks) and MP1207 (yellow sticks) in wild type KOR showing MP1207 chair form engaging D223 and E209 residues in TM5-ECL2 region while MP1202 boat form not engaging this …
(A) Dose-response curve: Groups of C57BL/6J mice were supraspinally (icv) administered MP1207, MP1208, morphine and U50,488h and antinociception measured using the 55°C tail withdrawal assay at peak …
Mice were administered either saline (n = 15), vehicle (n = 24), morphine (30 mg/kg, IP; n = 12 or 30 nmol; n = 18 or 100 nmol, icv; n = 16), MP1207 (30 nmol; n = 26 or 100 nmol icv, n = 10), MP1208 …
(A) MP1104 targets the TM2-TM3 region and is arrestin-biased at mMOR: The preferred docking pose of MP1104 (boat form, yellow stick) at an active state of MOR is shown. Ring C of MP1104 in boat form …
A) MP1104 targets the TM2-TM3 region and is arrestin biased at rKOR: The preferred docking pose of MP1104 (boat form, yellow stick) at an active state of KOR is shown. The iodophenylamido moiety …
(A–B) At hMOR, IBNtxA (orange) is a G protein biased agonist compared with DAMGO (blue) (N = 4). (C–D) At hKOR, IBNtxA (pink) is a full agonist in cAMP inhibition (N = 3) and Tango-arrestin …
Bias analysis for signaling was performed as described in Materials and methods. Data analyzed against DAMGO and/or U50,488h for each ligand using unpaired t-test with Welch’s correction. At hKOR, …
Note: possible engagement of residues D223 and E209 similar to MP1207 and MP1208 in TM5-ECL2 region.
MP1207 was screened against 330 non-olfactory GPCRs for agonism in the arrestin recruitment TANGO assay. Each point shows luminescence normalized to basal level at a given GPCR at 3 µM MP1207 dose (>…
MP1202 flips to a G protein biased agonist and arrestin recruitment for MP1207 and MP1208 is reduced. (A and C) At Y312W-hKOR, MP1202 (light green) is a G-biased agonist in cAMP inhibition (N = 3) (A…
(A-B) Methoxycarbonyl fentanyl (red) is a full agonist at hMOR in cAMP (N = 3) and arrestin recruitment assays (N = 3) compared to DAMGO (blue). (C–D) Methoxycarbonyl fentanyl (red) is a full …
(A-B) MP1305 (green) is a full agonist at hKOR in cAMP inhibition (N = 6) and partial agonist in Tango-arrestin recruitment assays (N = 6) compared to U50,488H (purple) at hKOR. (C–D) MP1305 (red) …
Docking pose for ligands inside active state KOR shown in white carbon sticks and white ribbon representations. (A–B) MP1202 in KOR favors boat conformation. (C–D) MP1305 in KOR favors chair …
Mice were administered icv either morphine (30 nmol; n = 18), MP1207 (30 nmol; n = 26) or MP1208 (35 nmol; n = 10) and the ambulation of each group of mice monitored using the CLAMS/Oxymax system. Mo…
Compd. | Ki [nM]a | ||||
---|---|---|---|---|---|
mMOR | mKOR | mDOR | |||
IBNtxA | 0.11 ± 0.02 | 0.03 ± 0.001 | 0.24 ± 0.05 | ||
MP1104 | 0.021 ± 0.00 | 0.0064 ± 0.0 | 0.08 ± 0.01 | ||
MP1202 | 0.071 ± 0.031 | 0.11 ± 0.064 | 1.3 ± 0.8 | ||
MP1207 | 0.23 ± 0.02 | 0.39 ± 0.05 | 15.62 ± 2.64 | ||
MP1208 | 0.34 ± 0.01 | 0.28 ± 0.02 | 19.28 ± 6.48 | ||
MP1305 | 0.25 ± 0.02 | 2.5 ±0.3 | 11.7 ± 1.4 | ||
MP1601 | 0.2 ± 0.01 | 2.13 ± 0.3 | 5.37 ± 0.9 | ||
Morphine | 4.60 ± 1.81b | _ | _ | ||
DAMGO | 3.34 ± 0.43b | _ | _ | ||
U50, 488h | _ | 0.73 ± 0.32b | _ | ||
DPDPE | _ | _ | 1.39 ± 0.67b |
Compd. | mMOR | mKOR | mDOR | |||||||
---|---|---|---|---|---|---|---|---|---|---|
EC50 (nM) | Emax (%) | EC50 (nM) | Emax (%) | EC50 (nM) | Emax (%) | IC50 (nM) | ||||
IBNtxA | 0.49 ± 0.12 | 101 ± 3 | 0.22 ± 0.02 | 102 ± 4 | 4.08 ± 0.67 | 95 ± 2 | - | |||
MP1104 | 0.21 ± 0.03 | 103 ± 2 | 0.027 ± 0.002 | 104 ± 2 | 0.41 ± 0.11 | 88 ± 0 | - | |||
MP1202 | 0.32 ± 0.03 | 68 ± 1 | 0.13 ± 0.02 | 94 ± 5 | 4 ± 1.6 | 71 ± 2 | - | |||
MP1207 | 1.29 ±0.65 | 41 ± 1 | 1.52 ± 0.07 | 39.3 ± 1.3 | nd | 10-15% | 27.34±1.95 | |||
MP1208 | 1.13 ± 0.05 | 54 ± 0.7 | 1.36 ± 0.23 | 43 ± 0.8 | nd | 10-15% | 11.39±0.3 | |||
MP1305 | 0.7 ± 0.1 | 81.2 ± 16 | 7.4 ± 1.8 | 42.2 ± 5.3 | 31.7 ± 3.6 | 22± 0.9 | - | |||
MP1601 | 0.5 ± 0.2 | 45 ± 4.6 | 3 ± 0.7 | 72 ± 4.5 | 10 ± 1.6 | 67 ± 3.9 | - | |||
DAMGO | 3.4 ± 0.2 | - | - | - | - | - | - | |||
U50,488h | - | - | 9.5 ± 1.8 | - | - | - | - | - | ||
DPDPE | - | - | - | - | 16.2 ± 5.1 | - | - | |||
Morphine | 14.77±3.9 | 102±5 | - | - | - | - | - | |||
Buprenorphineb | 1.8(1.3,2.3)c | Full agonistd | - | - | - | - | - |
Ligand (Basis set) | Energy(Chair – Boat) HF |
Energy(Chair – Boat) kcal/mol | Energy(Chair – Boat) kJ/mol |
---|---|---|---|
MP1104 (LanL2DZ) | 0.03671637 | 23.0396323 | 96.3988294 |
MP1104 (DGDZVP) | 0.03493887 | 21.9242457 | 91.7320032 |
IBNtxA (LanL2DZ) | −0.0014450 | −0.90674184 | −3.7938475 |
IBNtxA (DGDZVP) | −0.0016583 | −1.040599833 | −4.353869701 |
MP1202 (LanL2DZ) | −0.01402513 | −8.8009031585 | −36.822978815 |
MP1202 (DGDZVP) | −0.011652 | −7.31174652 | −30.59234743997 |
Drugs | MP1104 | IBNtxA | MP1202 | MP1207 | MP1208 | MP1305 | MP1601 | 6'GNTI | MP1209 | MP1210 |
---|---|---|---|---|---|---|---|---|---|---|
Docking score of Chair/hMOR | -36.22 | -52.42 | -55.04 | -69.74 | -38.63 | -40.61 | -51.03 | -44.17 | ||
Boat /hMOR | -48.28 | -31.36 | -49.44 | -50.81 | -67.72 | -28.83 | -38.23 | -43.67 | -36.18 | |
Chair /hKOR | -46.93 | -47.82 | -55.99 | -86.24 | -46.77 | -46.08 | -64.86 | -57.63 | -53.91 | |
Boat /hKOR | -55.06 | -49.51 | -52.42 | -45.9 | -65.88 | -44.87 | -47.54 | -60.77 | -55.43 |
Serial | R | Chair score | Boat score | Scores for chair preference |
---|---|---|---|---|
1 | -mNH2 | −55.35 | −58.47 | +3.12 |
2 | -mN(CH3)2 | −51.81 | −48.34 | −3.47 |
3 | -mOH | −54.81 | −57.34 | +2.53 |
4 (MP1207) | -mCH2NH2 | −55.99 | −45.9 | −10.09 |
5 | -mCH2CH2NH2 | −59.42 | −51.79 | −7.63 |
6 | -mCH2CH2CH2NH2 | −64.07 | −49.91 | −14.16 |
7 | -mCH2CH2CH2CH2NH2 | −52.42 | −49.67 | −2.75 |
8 | -mgaunidine | −76.29 | −66.34 | −9.95 |
9 (MP1208) | -mCH2guanidine | −86.24 | −65.88 | −20.36 |
10 | -mCOguanidine | −82.09 | −77.53 | −4.56 |
11 | -pCH2NH2 | −57.63 | −60.77 | +3.14 |
12 | -mCH2OH | −53.91 | −55.43 | +1.5 |
Functional data at hDOR and mDOR | |||||
---|---|---|---|---|---|
Compd. | cAMP inhibition | Arrestin recruitment | |||
EC50,nM (pEC50± SEM) | Emax%± SEM | EC50,nM (pEC50± SEM) | Emax%± SEM | ||
IBNtxA | 0.43 (9.3 ± 0.03) | 106 ± 1 | 14.1(7.8 ± 0.06) | 224±5 | |
DPDPE (CTRL.) | 0.69 (9.1 ± 0.07) | 100 ± 2 | 2.99(8.5 ± 0.04) | 100±1.5 | |
MP1104 | 0.40 (9.4 ± 0.04) | 99 ± 1.1 | 3.73 (8.4 ± 0.06) | 189 ± 5.5 | |
DADLE (CTRL.) | 0.66(9.2 ± 0.05) | 100 ± 1.3 | 0.349 (9.45 ± 0.10) | 100 ± 3.2 | |
MP1202 | 8.18(8.1 ± 0.06) | 99 ± 2.2 | 18.14(7.7 ± 0.25) | 26 ± 3.1 | |
DADLE (CTRL.) | 1.45(8.8 ± 0.06) | 100 ± 2 | 8.41(8.1 ± 0.08) | 100 ± 2.7 | |
MP1207 | 11.4 (7.9 ± 0.1) | 38 ± 2 | 64.06(7.2 ± 0.23) | 34 ± 3.7 | |
MP1208 | 2.49 (8.6 ± 0.13) | 39 ±1.8 | 3624.0(5.5 ± 0.27) | 62±16.7 | |
DADLE (CTRL.) | 0.48 (9.3 ± 0.05) | 100 ±1.5 | 1.41 (8.8 ± 0.07) | 100±2.3 | |
MP1305 | 74.18 (7.1 ± 0.08) | 71 ± 2.4 | 227.5(6.6 ± 0.06) | 89 ± 2.8 | |
MP1601 | 2.76(8.6 ± 0.06) | 106 ± 2.3 | 86.7(7.1 ± 0.06) | 203±5.4 | |
DPDPE(CTRL.) | 0.69 (9.1 ± 0.07) | 100 ± 2 | 2.99(8.5 ± 0.04) | 100±1.5 | |
B. Functional data at mDOR using BRET assays | |||||
Compd. | G protein activation | Arrestin recruitment | |||
EC50,nM (pEC50± SEM) | Emax%± SEM | EC50,nM (pEC50± SEM) | Emax%± SEM | ||
IBNtxA | 0.48(9.3 ± 0.10) | 108 ± 3.7 | 26.6(7.5 ± 0.2) | 88 ± 6.8 | |
DPDPE(CTRL.) | 2.72(8.5 ± 0.09) | 100 ± 3 | 184.3(6.73 ± 0.1) | 100 ± 6.4 | |
MP1104 | 1.4(8.9 ± 0.06) | 91 ± 1.7 | 26.0(7.6 ± 0.11) | 40 ± 1.7 | |
DPDPE(CTRL.) | 1.3(8.9 ± 0.04) | 100 ± 1.2 | 98.0(7.0 ± 0.04) | 100 ± 1.8 | |
MP1202 | 7.03(8.1 ± 0.15) | 103 ± 4.6 | 524.8(6.3 ± 0.20) | 26 ± 2.3 | |
DPDPE(CTRL.) | 2.19(8.6 ± 0.10) | 100 ± 3.5 | 109.3(6.7 ± 0.06) | 100 ± 3 | |
MP1207 | 116.4(6.9 ± 0.12) | 52 ± 2.3 | nd | nd | |
MP1208 | 26.6(7.6 ± 0.20) | 58 ± 3.3 | nd | nd | |
MP1305 | 40.4(7.4 ± 0.20) | 105 ± 5.9 | nd | nd | |
MP1601 | 6.27(8.2 ± 0.20) | 105 ± 6.7 | 9.0 (8.0 ± 0.33) | 16 ± 1.4 | |
DPDPE(CTRL.) | 0.44(9.3 ± 0.13) | 100 ± 2.5 | 21.8 (7.6 ± 0.04) | 100 ± 1.3 |
Receptors | Compounds | cAMP inhibition (Gi) assay | Arrestin recruitment (Tango) assay | Figure | ||
---|---|---|---|---|---|---|
EC50 (pEC50± SEM) | Emax%± SEM | EC50 (pEC50± SEM) | Emax%± SEM | |||
hMOR | MP1104 | 0.074 (10.13 ± 0.05) nM | 94±1 | 0.573(9.24±0.08) nM | 90±2.28 | Figure 2A–B |
DAMGO | 0.84(9.07±0.08) nM | 100 | 13.9 (7.86±0.06) nM | 100 | ||
hKOR | MP1104 | 0.00327 (11.49±0.035) nM | 10±1.64 | 0.03944(10.4±0.06) nM | 117 ± 2 | Figure 2C–D |
U50488h | 0.089(10.05±0.04) nM | 100 | 3.6(8.44±0.04) nM | 100 | ||
hMOR | MP1202 | 0.077 (10.11 ± 0.06) nM | 92±1.4 | 26.8(7.57±0.1) nM | 53±2 | Figure 2G–H |
DAMGO | 3.78(8.4±0.06) nM | 100 | 58.8(7.23±0.06) nM | 100 | ||
hKOR | MP1202 | 0.00139 (11.86±0.05) nM, | 97.9±2.5 | 0.0457(10.34±0.05) nM | 101±1 | Figure 2I–J |
U50,488h | 0.006 (10.2±0.056) nM | 100 | 3.6(8.44±0.04) nM | 100 | ||
hKOR | MP1207 | 0.11 (9.98 ± 0.07) nM | 90±1.7 | 3.97(8.4±0.18) nM | 37±2 | Figure 3A–B |
MP1208 | 0.14 (9.9 ± 0.07) nM | 96±1.9 | 16.41(7.79±0.14) nM | 48±2.4 | ||
U50,488h | 0.64(9.2±0.06) nM | 100 | 7.55(8.12±0.06) nM | 100 | ||
hMOR | MP1207 | 0.034 (10.47 ± 0.15) nM | 33±1.4 | nd | nd | Figure 3E–F |
MP1208 | 0.008 (8.73 ± 0.12) nM | 42±1.3 | nd | nd | ||
U50,488h | 1.86(8.73±0.06) nM | 100 | ||||
hKOR | MP1209 | 0.024 (10.6 ± 0.05) nM | 100±1.23 | 0.37(9.43 ± 0.19) nM | 67±3 | Figure 4E–F |
MP1210 | 0.025 (10.6 ± 0.05) nM | 101.1±1.1 | 1.16 (8.94 ± 0.17) nM | 63±3.3 | ||
U50,488h | 0.05 (10.29±0.06) nM | 100 | 7.85 (8.11±0.1) nM. | 100 | ||
hMOR | MP1209 | 0.25(9.61 ± 0.04) nM | 98.5±0.96 | nd | nd | Figure 4G–H |
MP1210 | 0.15(9.81 ± 0.05) nM | 94.6±0.98 | nd | nd | ||
DAMGO | 0.2 (9.7±0.06) nM | 100 | ||||
hMOR | Methoxycarbonyl fentanyl | 0.099 (10 ± 0.06) nM | 103±1.8 | 18.94 (7.7±0.1) nM | 194±8 | Appendix 1—figure 8A–B |
DAMGO | 2.58 (8.59±0.07) nM | 100 | 404.1(6.39±0.05) nM | 100 | ||
hMOR | MP102 | 19.7(7.7 ± 0.08) nM | 87±2.66 | nd | nd | Appendix 1—figure 8F–G |
DAMGO | 2.58 (8.59±0.07) nM | 100 | ||||
Morphine | 21.8 (7.66 ± 0.08) nM | 97±3.06 | 888 (6.05±0.25) nM | 25.32±4.4 | ||
hMOR | DAMGO | 8.1 (8.09 ± 0.06) nM | 100 | 140.7 (6.85±0.08) nM | 100 | |
Buprenorphine | 0.7 (10.14 ± 0.11) pM | 75±2.36 | 1.79 (8.75±0.13) nM | 43±2 | ||
DAMGO | 4.36 (8.36 ± 0.08) nM | 100 | 22 (7.64±0.063) nM | 100 | ||
Receptors | Compounds | G protein activation (BRET) assay | Arrestin recruitment (BRET) assay | Figure | ||
EC50 (pEC50± SEM) | Emax%± SEM | EC50 (pEC50± SEM) | Emax%± SEM | |||
mMOR | MP1207 | 3.61 (8.44 ± 0.26) nM | 42±2.6 | nd | nd | Figure 3I–J |
MP1208 | 2.27 (8.64 ± 0.29) nM | 41±3 | nd | nd | ||
DAMGO | 3.27(8.49±0.08) nM | 100 | ||||
DAMGO | 9.09 (8.04 ± 0.13) nM | 100 | ||||
mMOR | Morphine | 9.09 (8.04 ± 0.13) nM | 109±3.1 | |||
Buprenorphine | 1.17 (8.93 ± 0.14) nM | 59±2.4 | ||||
Receptors | Compound | G protein activation (BRET) assay | Arrestin recruitment (BRET) assay | Figure | |||
---|---|---|---|---|---|---|---|
EC50 (pEC50± SEM) | Emax%± SEM | EC50 (pEC50± SEM) | Emax%± SEM | ||||
mMOR | MP1104 | 0.66 (9.2±0.11) nM | 62±2 | 0.285 (9.55±0.12) nM | 53 ± 1.6 | Appendix 1—figure 1A | |
DAMGO | 7.3 (8.1±0.07) nM | 100 | 31.5 (7.5±0.06) nM | 100 | |||
IBNtxA | 0.054(10.3 ± 0.02) nM | 59±2.2 | 11.32(4.9±0.3) µM | 75±13.9 | Appendix 1—figure 1B | ||
DAMGO | 12.9(7.8±0.06) nM | 100 | 0.77(6.11±0.16) µM | 100 | |||
MP1202 | 0.63 (9.2±0.09) nM | 61±1.5 | 3140 (5.5±0.28) nM | 53 ± 1.6 | Appendix 1—figure 1C | ||
DAMGO | 6.31 (8.2±0.07) nM | 100 | 114 (6.9±0.15) nM | 100 | |||
MP1207 | 3.61 (8.44 ± 0.26) nM | 42±2.6 | nd | nd | Appendix 1—figure 1D | ||
MP1208 | 2.27 (8.64 ± 0.29) nM | 41±3 | nd | nd | |||
DAMGO | 3.27(8.49±0.08) nM | 100 | |||||
MP1305 | 0.74(9.1 ± 0.12) nM | 72±2 | nd | nd | Appendix 1—figure 1E | ||
DAMGO | 3.3(8.4±0.08) nM | 100 | |||||
MP1601 | 2.2(8.6 ± 0.3) nM | 49±3 | nd | nd | |||
DAMGO | 0.9(9.0±0.1) nM | 100 | |||||
rKOR | MP1104 | 0.073 (10.14±0.04) nM | 93±1 | 1.14(8.94±0.07) nM | 89 ± 2.6 | Appendix 1—figure 2A | |
U50, 488h | 1.05(8.98±0.03) nM | 100 | 110(6.95±0.05) nM | 100 | |||
IBNtxA | 0.064(10.2 ± 0.1) nM | 101±2.3 | 1.23(8.9±0.02) nM | 133±7.3 | Appendix 1—figure 2B | ||
U50, 488h | 27.7(7.6±0.01)nM | 100 | 345.6(6.4±0.03) nM | 100 | |||
MP1202 | 0.134(9.87±0.09) nM | 104±2 | 1.44(8.84±0.25) nM | 77 ± 5 | Appendix 1—figure 2C | ||
U50, 488h | 4.79 (8.32±0.07) nM | 100 | 235(6.63±0.18) nM | 100 | |||
MP1207 | 1.13 (8.95 ± 0.31) nM | 32±2.3 | nd | nd | Appendix 1—figure 2D | ||
MP1208 | 1.1(8.97 ± 0.29) nM | 40±2.4 | nd | nd | |||
U50, 488h | 82.6(7.1±0.09) nM | 100 | |||||
MP1305 | 5.04 (8.3 ± 0.32) nM | 35±3 | nd | nd | Appendix 1—figure 2E | ||
U50, 488h | 40.3(7.4±0.07) nM | 100 | |||||
MP1601 | 8.9(8.1 ± 0.12) nM | 75±3 | 56.5(7.2±0.23) nM | 37±3 | |||
U50, 488h | 26.7(7.6±0.09) nM | 100 | 169.6(6.7±0.07) nM | 100 | |||
mMOR | IBNtxA | 0.054(10.3 ± 0.02) nM | 59±2.2 | 11.32(4.9±0.3) µM | 75±13.9 | Figure 3F–G | |
DAMGO | 12.9(7.8±0.06) nM | 100 | 0.77(6.11±0.16) µM | 100 | |||
rKOR | IBNtxA | 0.064(10.2 ± 0.1) nM | 101±2.3 | 1.23(8.9±0.02) nM | 133±7.3 | Figure 3H–I | |
U50, 488h | 27.7(7.6±0.01) nM | 100 | 345.6(6.4±0.03) nM | 100 | |||
mMOR | Methoxycarbonyl fentanyl | 0.21(9.7 ± 0.04) nM | 109±0.94 | 1.96(8.71±0.11) nM | 63±1.8 | Appendix 1—figure 7C–D | |
DAMGO | 1.73(8.76±0.05) nM | 100 | 110.1(6.96±0.06) nM | 100 | |||
MP102 | 404.5 (6.39 ± 0.2) nM | 78±7 | nd | nd | Appendix 1—figure 7E | ||
DAMGO | 3.27(8.5±2) nM | 100 |
Receptors | Compounds | cAMP inhibition (Gi) assay | Arrestin recruitment (Tango) assay | Figure | |||
---|---|---|---|---|---|---|---|
EC50 (pEC50± SEM) | Emax%± SEM | EC50 (pEC50± SEM) | Emax%± SEM | ||||
hMOR | IBNtxA | 0.07(10.2 ± 0.006) nM | 95±2 | 5.86(8.2±0.002) nM | 29±0.02 | Appendix 1—figure 3A-B | |
DAMGO | 0.99(9.0±0.007) nM | 100 | 14.16(7.9±0.003) nM | 100 | |||
hKOR | IBNtxA | 2.46 (11.6 ± 0.037) pM | 101±1.79 | 0.013(10.9±0.07) nM | 109±1.8 | Appendix 1—figure 3C-D | |
U50488h | 0.089(10.05±0.042) nM | 100 | 3.63(8.4±0.03) nM | 100 | |||
Y312W-hKOR | MP1202 | 0.21 (10.69 ± 0.07)pM | 101±1.5 | 3.4(8.5±0.14) nM | 55±2.6 | Appendix 1—figure 7A,C | |
U50,488h | 2.7(8.56±0.06)nM | 100 | 0.63(7.2±0.06) nM | 100 | |||
WT-hKOR | MP1202 | 0.0457(10.34±0.05) nM | 101±1 | Appendix 1—figure 7B,D | |||
U50,488h | 3.6(8.44±0.04) nM | 100 | |||||
WT-hMOR | MP1202 | 26.8(7.57±0.1) nM | 53±2 | ||||
DAMGO | 58.8(7.23±0.06) nM | 100 | |||||
Y312W-hKOR | MP1207 | 0.16 (9.8 ± 0.08) nM | 95±1.8 | nd | nd | Appendix 1—figure 7E,G | |
MP1208 | 0.36 (10.44 ± 0.05) pM | 97±1 | nd | nd | |||
U50,488h | 0.92(9.04±0.04)nM | 100 | 14(7.85±0.1) nM | 100 | |||
WT-hKOR | MP1207 | 3.97(8.4±0.18) nM | 37±2 | nd | nd | Appendix 1—figure 7F | |
MP1208 | 16.41(7.79±0.14) nM | 48±2.4 | nd | nd | |||
U50,488h | 7.55(8.12±0.06) nM | 100 | |||||
hKOR | MP1305 | 0.72 (9.14 ± 0.05) nM | 102±1.2 | 25.72(7.6±0.04) nM | 75±1 | Appendix 1—figure 9A-B | |
U50, 488h | 0.076(10.11±0.04) nM | 100 | 3.6(8.44±0.04) nM | 100 | |||
hMOR | MP1305 | 0.12(9.9 ± 0.12) nM | 69±1.8 | 16.4(7.8±0.3) nM | 21±3 | Appendix 1—figure 9C-D | |
DAMGO | 3.88(8.4±0.05) nM | 100 | 168.1(6.77±0.09) nM | 100 | |||
hKOR | MP1601 | 0.17(9.76 ± 0.05) nM | 109±1 | 3.23(8.49±0.07) nM | 107±3 | Appendix 1—figure 9E-F | |
U50, 488h | 0.077(10.11±0.04) nM | 100 | 3.6(8.44±0.04) nM | 100 | |||
hMOR | MP1601 | 0.1(9.99 ± 0.09) nM | 69±1 | 4.02(8.4±0.2) nM | 27±2 | Appendix 1—figure 9G-H | |
DAMGO | 3.88(8.4±0.05) nM | 100 | 168.1(6.77±0.09) nM | 100 |
Drug | Receptor | cAMP | Tango | ΔlogRA | ΔlogRA | ΔΔlog RA | Bias factor | Figure |
---|---|---|---|---|---|---|---|---|
Log RA | LogRA | cAMP | Tango | (cAMP-Tango) | (cAMP-Tango) | |||
U50,488h | hKOR | 10.09±0.035 | 8.29±0.019 | 0±0.049 | 0±0.027 | 0±0.056 | 1 | Appendix 1—figure 4A |
MP1104 | hKOR | 11.44±0.034 | 10.45±0.019 | 1.35±0.048 | 2.16±0.027 | -0.81±0.055 | 0.15 | |
U50,488h | hKOR | 10.22±0.051 | 8.44±0.004 | 0±0.072 | 0±0.006 | 0±0.070 | 1 | Appendix 1—figure 4A |
MP1202 | hKOR | 11.88±0.050 | 10.30±0.004 | 1.66±0.072 | 1.856±0.006 | -0.19±0.072 | nd | |
U50,488h | hKOR | 10.06±0.036 | 8.36±0.011 | 0±0.051 | 0±0.015 | 0±0.050 | 1 | Appendix 1—figure 4A |
IBNtxA | hKOR | 11.59±0.036 | 10.89±0.010 | 1.53±0.050 | 2.53±0.015 | -1.002±0.052 | 0.10 | |
U50,488h | hKOR | 9.175±0.004 | 8.14±0.007 | 0±0.005 | 0±0.010 | 0±0.012 | 1 | Appendix 1—figure 4A |
MP1207 | hKOR | 9.902±0.004 | 7.97±0.024 | 0.73±0.006 | -0.176±0.025 | 0.903±0.026 | 8.00 | |
U50,488h | hKOR | 9.176±0.004 | 8.14±0.008 | 0±0.005 | 0±0.011 | 0±0.012 | 1 | Appendix 1—figure 4A |
MP1208 | hKOR | 9.83±0.004 | 7.447±0.020 | 0.65±0.005 | -0.697±0.022 | 1.35±0.022 | 22 | |
U50,488h | hKOR | 10.42±0.06 | 8.37±0.22 | 0±0.084 | 0±0.31 | 0±0.32 | 1 | Appendix 1—figure 4A |
MP1209 | hKOR | 10.55±0.06 | 8.735±0.220 | 0.13±0.084 | 0.368±0.31 | -0.238±0.32 | nd | |
U50,488h | hKOR | 10.39±0.06 | 8.096±0.084 | 0±0.081 | 0±0.12 | 0±0.144 | 1 | Appendix 1—figure 4A |
MP1210 | hKOR | 10.59±0.06 | 8.576±0.156 | 0.2±0.081 | 0.48±0.18 | -0.28±0.19 | nd | |
U50,488h | hKOR | 10.010±0.012 | 8.507±0.026 | 0±0.017 | 0±0.037 | 0±0.041 | 1 | Appendix 1—figure 4A |
MP1305 | hKOR | 9.22±0.012 | 7.17±0.025 | -0.79±0.017 | -1.341±0.036 | 0.55±0.04 | 4 | |
U50,488h | hKOR | 10.03±0.014 | 8.414±0.009 | 0±0.020 | 0±0.012 | 0±0.023 | 1 | Appendix 1—figure 4A |
MP1601 | hKOR | 9.85±0.014 | 8.51±0.009 | -0.19±0.020 | 0.097±0.012 | -0.282±0.023 | 0.52 | |
DAMGO | hMOR | 9.102±0.009 | 7.925±0.013 | 0±0.012 | 0±0.019 | 0±0.022 | 1 | Appendix 1—figure 4B |
MP1104 | hMOR | 10.12±0.009 | 9.18±0.013 | 1.018±0.012 | 1.26±0.019 | -0.24±0.022 | 0.58 | |
DAMGO | hMOR | 8.44±0.011 | 7.18±0.001 | 0±0.015 | 0±0.001 | 0±0.015 | 1 | Appendix 1—figure 4B |
MP1202 | hMOR | 9.99±0.012 | 7.24±0.002 | 1.55±0.016 | 0.058±0.002 | 1.49±0.016 | 31 | |
DAMGO | hMOR | 8.86±0.075 | 7.82±0.060 | 0±0.106 | 0±0.084 | 0±0.135 | 1 | Appendix 1—figure 4B |
IBNtxA | hMOR | 9.99±0.081 | 7.572±0.25 | 1.14±0.11 | -0.25±0.25 | 1.38±0.28 | 24 | |
DAMGO | hMOR | 8.62±0.054 | 6.78±0.010 | 0±0.076 | 0±0.014 | 0±0.077 | 1 | Appendix 1—figure 4B |
MP1305 | hMOR | 9.79±0.053 | 6.89±0.048 | 1.17±0.076 | 0.109±0.049 | 1.059±0.090 | 11 | |
DAMGO | hMOR | 8.40±0.001 | 6.78±0.009 | 0±0.002 | 0±0.012 | 0±0.013 | 1 | Appendix 1—figure 4B |
MP1601 | hMOR | 9.84±0.002 | 7.65±0.035 | 1.44±0.002 | 0.87±0.036 | 0.57±0.036 | 4 | |
U50,488h | WT hKOR | 10.22±0.051 | 8.44±0.004 | 0±0.072 | 0±0.006 | 0±0.070 | 1 | Appendix 1—figure 7L |
MP1202 | WT hKOR | 11.88±0.050 | 10.30±0.004 | 1.66±0.072 | 1.856±0.006 | -0.19±0.072 | nd | |
U50,488h | Y312W-hKOR | 8.568±0.005 | 7.559±0.051 | 0±0.007 | 0±0.072 | 0±0.073 | 1 | Appendix 1—figure 7L |
MP1202 | Y312W-hKOR | 10.63±0.005 | 8.091±0.051 | 2.062±0.007 | 0.532±0.073 | 1.53±0.073 | 34 | |
DAMGO | hMOR | 8.563±0.004 | 5.037±0.176 | 0±0.006 | 0±0.249 | 0±0.249 | 1 | Appendix 1—figure 8J |
Methoxycarbonyl | hMOR | 10.020±0.004 | 7.546±0.184 | 1.457±0.006 | 2.509±0.255 | -1.052±0.255 | 0.09 | |
fentanyl |
Drug | Receptor | BRET-G | BRET-Arr | ΔlogRA | ΔlogRA | ΔΔlog RA | Bias factor | Figure | |
---|---|---|---|---|---|---|---|---|---|
Log RA | LogRA | BRET-G | BRET-arr | (BRETG-BRETArr) | (BRETG-BRETArr) | ||||
U50,488h | rKOR | 9.003±0.044 | 7.14±0.034 | 0±0.062 | 0±0.047 | 0±0.078 | 1 | Appendix 1—figure 4C | |
MP1104 | rKOR | 10.07±0.047 | 8.84±0.033 | 1.067±0.064 | 1.702±0.047 | -0.64±0.079 | 0.23 | ||
U50,488h | rKOR | 8.312±0.077 | 6.798±0.168 | 0±0.109 | 0±0.238 | 0±0.261 | 1 | Appendix 1—figure 4C | |
MP1202 | rKOR | 9.906±0.088 | 8.791±0.171 | 1.594±0.117 | 1.993±0.239 | -0.399±0.27 | nd | ||
U50,488h | rKOR | 7.55±0.103 | 5.988±0.222 | 0±0.146 | 0±0.313 | 0±0.345 | 1 | Appendix 1—figure 4C | |
IBNtxA | rKOR | 10.19±0.141 | 8.846±0.266 | 2.64±0.175 | 2.858±0.346 | -0.218±0.388 | nd | ||
U50,488h | rKOR | 7.593±0.012 | 6.783±0.005 | 0±0.016 | 0±0.007 | 0±0.018 | 1 | Appendix 1—figure 4C | |
MP1601 | rKOR | 7.917±0.018 | 7.113±0.052 | 0.324±0.052 | 0.33±0.052 | -0.006±0.057 | nd | ||
DAMGO | mMOR | 8.56±0.12 | 7.873±0.06 | 0±0.176 | 0±0.09 | 0±0.197 | 1 | Appendix 1—figure 4C | |
MP1104 | mMOR | 8.917±0.12 | 9.196±0.06 | 0.357±0.173 | 1.323±0.09 | -0.966±0.195 | 0.11 | ||
DAMGO | mMOR | 8.713±0.013 | 7.291±0.044 | 0±0.019 | 0±0.063 | 0±0.066 | 1 | Appendix 1—figure 8J | |
Methoxycarbonyl | mMOR | 9.697±0.013 | 8.464±0.045 | 0.984±0.019 | 1.173±0.063 | -0.189±0.066 | nd | ||
fentanyl |
Analgesia and CLAMS data.